Synthesis and Anti-bacterial Activity of New Substituted 2-trifluoromethyl-4-quinolinylhydrazone Analogs against Mycobacterium
Tuberculosis Strains

Emerson   Teixeira   da Silva; Gabriel   Fernandes   de Andrade; Maria   Cristina Silva   Lourenço; Marcus   Vinicius Nora   De Souza

doi:10.2174/0109298673267136231003113803

Note! Please note that this article is currently in the "Article in Press" stage and is not the final "Version of record". While it has been accepted, copy-edited, and formatted, however, it is still undergoing proofreading and corrections by the authors. Therefore, the text may still change before the final publication. Although "Articles in Press" may not have all bibliographic details available, the DOI and the year of online publication can still be used to cite them. The article title, DOI, publication year, and author(s) should all be included in the citation format. Once the final "Version of record" becomes available the "Article in Press" will be replaced by that.

Abstract

Background: Tuberculosis (TB) is a serious disease that still affects humanity, despite being old, caused by the bacterium Mycobacterium tuberculosis (Mtb). The emergence of drug-resistant strains has alarmed governments and international organizations, such as the World Health Organization (WHO). The need for research on new drugs that are effective in a shorter treatment time and active against resistant strains still persists.

Objective: The objective of this study is to synthesize and evaluate forty-four substituted 2-trifluoromethyl-4-quinolinylhydrazone analogs, as probable inhibitors of Mycobacterium tuberculosis growth.

Methods: The anti-mycobacterial activities of all tested compounds against Mycobacterium tuberculosis strains, as well as the cytotoxicity test, were evaluated using the in vitro microplate procedure with broth microdilution assay.

Results: Thirteen compounds exhibited some activity against sensitive strain ATCC 27294, six of which were the most active: 4a, 4c, 6a, 6b, 6c, and 6g; with MIC around 7 - 8 μM, close to that presented by ethambutol (15.9 μM), a drug used in the treatment of tuberculosis. These same compounds also were active against a resistant strain of Mtb (T113), with MIC around 7 – 8 μM. Three of these compounds 4a, 6a, and 6c were not cytotoxic against Vero cells at concentrations near the MIC.

Conclusion: This study indicates the importance of the hydrazone function to obtain promising anti-TB compounds and open new perspectives for drug development.

[1]
 Tuberculosis Report, Global Tuberculosis Report 2021, World Health Organization. Available from:
          https://www.who.int/publications/i/item/9789240037021 (accessed January 25, 2023).

[2]
Chahine, E.B.; Dougherty, J.A.; Thornby, K-A.; Guirguis, E.H. Antibiotic approvals in the last decade: Are we keeping up with resistance. Ann. Pharmacother.,  2022, 56(4), 441-462.
 [http://dx.doi.org/10.1177/10600280211031390] [PMID:  34259076]

[3]
Villamizar-Mogotocoro, A.F.; Vargas-Méndez, L.Y.; Kouznetsov, V.V. Pyridine and quinoline molecules as crucial protagonists in the never-stopping discovery of new agents against tuberculosis. Eur. J. Pharm. Sci.,  2020, 151, 105374.
 [http://dx.doi.org/10.1016/j.ejps.2020.105374] [PMID:  32450221]

[4]
Roberto Chiarelli, L.; Mori, G.; Esposito, M.; Silvia Orena, B.; Rosalia Pasca, M. New and old hot drug targets in tuberculosis. Curr. Med. Chem.,  2016, 23(33), 3813-3846.
 [http://dx.doi.org/10.2174/1389557516666160831164925] [PMID:  27666933]

[5]
Keri, R.S.; Rajappa, C.K.; Patil, S.A.; Nagaraja, B.M. Benzimidazole-core as an antimycobacterial agent. Pharmacol. Rep.,  2016, 68(6), 1254-1265.
 [http://dx.doi.org/10.1016/j.pharep.2016.08.002] [PMID:  27686965]

[6]
Krátky, M.; Vinsova, J. Sulphur-containing heterocycles as antimycobacterial agents: Recent advances in thiophene and thiadiazole derivatives. Curr. Top. Med. Chem.,  2016, 16(26), 2921-2952.
 [http://dx.doi.org/10.2174/1568026616666160506131118] [PMID:  27150373]

[7]
Keri, R.S.; Sasidhar, B.S.; Nagaraja, B.M.; Santos, M.A. Recent progress in the drug development of coumarin derivatives as potent antituberculosis agents. Eur. J. Med. Chem.,  2015, 100, 257-269.
 [http://dx.doi.org/10.1016/j.ejmech.2015.06.017] [PMID:  26112067]

[8]
Mathew, B.; Suresh, J.; Ahsan, M.; Mathew, G.; Usman, D.; Subramanyan, P.; Safna, K.; Maddela, S. Hydrazones as a privileged structural linker in antitubercular agents: A review. Infect. Disord. Drug Targets,  2015, 15(2), 76-88.
 [http://dx.doi.org/10.2174/1871526515666150724104411] [PMID:  26205803]

[9]
Bonnett, S.A.; Dennison, D.; Files, M.; Bajpai, A.; Parish, T. A class of hydrazones are active against non-replicating Mycobacterium tuberculosis. PLoS One,  2018, 13(10), e0198059/1-e0198059/11.

[10]
Bryk, R.; Gold, B.; Venugopal, A.; Singh, J.; Samy, R.; Pupek, K.; Cao, H.; Popescu, C.; Gurney, M.; Hotha, S.; Cherian, J.; Rhee, K.; Ly, L.; Converse, P.J.; Ehrt, S.; Vandal, O.; Jiang, X.; Schneider, J.; Lin, G.; Nathan, C. Selective killing of nonreplicating mycobacteria. Cell Host Microbe,  2008, 3(3), 137-145.
 [http://dx.doi.org/10.1016/j.chom.2008.02.003]

[11]
Pinheiro, A.C.; Nogueira, T.C.M.; Pereira, G.E.; Lourenço, C.; de Souza, M.V.N. Synthesis and antimycobacterial evaluation of pyridinyl- and pyrazinylhydrazone derivatives. Med. Chem. Res.,  2020, 29(9), 1662-1668.
 [http://dx.doi.org/10.1007/s00044-020-02592-7]

[12]
da Silva, E.; da Silva Araújo, A.; Moraes, A.; de Souza, L.; Silva Lourenço, M.; de Souza, M.; Wardell, J.; Wardell, S. Synthesis and biological activities of camphor hydrazone and imine derivatives. Sci. Pharm.,  2015, 84(3), 467-483.
 [http://dx.doi.org/10.3390/scipharm84030467]

[13]
Nogueira, T.C.M.; dos Santos Cruz, L.; Lourenço, M.C.; de Souza, M.V.N. Design, synthesis and anti-tuberculosis activity of hydrazones and n-acylhydrazones containing vitamin b6 and different heteroaromatic nucleus. Lett. Drug Des. Discov.,  2019, 16(7), 792-798.
 [http://dx.doi.org/10.2174/1570180815666180627122055]

[14]
Pinto, L.S. da S.; de Souza, M.V.N.; Kaiser, C.R. Synthesis and evaluation of anti-tuberculosis and anti-cancer activities of hydrazones and N-acylhydrazones by using sonochemistry, a new general procedure. Lett. Drug Des. Discov.,  2017, 14, 678-685.

[15]
da Silva, E.T.; de Andrade, G.F.; Araújo, A.S.; Lourenço, M.C.S.; de Souza, M.V.N. Antibacterial activity of new substituted 4-N-alkylated-2-trifluoromethyl-quinoline analogues against sensitive and resistant Mycobacterium tuberculosis strains. Eur. J. Pharm. Sci.,  2021, 157, 105596.
 [http://dx.doi.org/10.1016/j.ejps.2020.105596]

[16]
Candéa, A.L.P.; Ferreira, M.L.; Pais, K.C.; Cardoso, L.N.F.; Kaiser, C.R.; Henriques, M.G.M.O.; Lourenço, M.C.S.; Bezerra, F.A.F.M.; de Souza, M.V.N. Synthesis and antitubercular activity of 7-chloro-4-quinolinylhydrazones derivatives. Bioorg. Med. Chem. Lett.,  2009, 19(22), 6272-6274.
 [http://dx.doi.org/10.1016/j.bmcl.2009.09.098] [PMID:  19819134]

[17]
de Andrade, G.F.; da Silva, E.T.; Lourenço, M.C.S.; de Souza, M.V.N. Synthesis and anti-bacterial activity evaluation against Mycobacterium tuberculosis of new quinoline derivatives coupled with the camphor nucleus. Lett. Org. Chem.,  2024, 21(2), 107-115.
 [http://dx.doi.org/10.2174/1570178620666230818092746]

[18]
Pinheiro, A.C.; Nogueira, T.C.M.; da Costa, C.F.; Lourenço, C.; Low, J.N.; Wardell, J.L.; Wardell, S.M.S.V.; de Souza, M.V.N. A study of antituberculosis activities and crystal structures of (E)-2-[2-(arylidene) hydrazinyl] pyrimidine and (E)-N1-(arylidene)pyrimidine-2-carbohydrazide derivatives. Z. Naturforsch. B. J. Chem. Sci.,  2020, 75(12), 1011-1028.
 [http://dx.doi.org/10.1515/znb-2020-0108]

[19]
Mosmann, T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Methods,  1983, 65(1-2), 55-63.
 [http://dx.doi.org/10.1016/0022-1759(83)90303-4] [PMID:  6606682]

[20]
Riss, T.L.; Moravec, R.A.; Niles, A.L.; Duellman, S.; Benink, H.A.; Worzella, T.J.; Minor, L. Cell Viability Assays in Assay Guidance Manual; Eli Lilly & Company and the National Center for Advancing Translational Sciences, 2016. https://www.ncbi.nlm.nih.gov/books/NBK53196/

[21]
Gonçalves, R.S.B.; Kaiser, C.R.; Lourenço, M.C.S.; Bezerra, F.A.F.M.; de Souza, M.V.N.; Wardell, J.L.; Wardell, S.M.S.V.; Henriques, M.G.M.O.; Costa, T. Mefloquine–oxazolidine derivatives, derived from mefloquine and arenecarbaldehydes: In vitro activity including against the multidrug-resistant tuberculosis strain T113. Bioorg. Med. Chem.,  2012, 20(1), 243-248.
 [http://dx.doi.org/10.1016/j.bmc.2011.11.006] [PMID:  22142615]

Rights & Permissions Print Cite

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/0109298673267136231003113803	Print ISSN 0929-8673
Publisher Name Bentham Science Publisher	Online ISSN 1875-533X

Current Medicinal Chemistry

Synthesis and Anti-bacterial Activity of New Substituted 2-trifluoromethyl-4-quinolinylhydrazone Analogs against Mycobacterium Tuberculosis Strains

Abstract Play Pause

Related Journals

Related Books

Abstract